KWM
PACB icon

Kingsview Wealth Management’s Pacific Biosciences PACB Stock Holding History

Kingsview Wealth Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.1K Hold
10,765
– – ﹤0.01% 1414
2026
Q1 		$14.2K Buy
10,765
+331
+3% +$592 ﹤0.01% 1326
2025
Q4 		$19.5K Buy
+10,434
New +$20.1K ﹤0.01% 1228

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Kingsview Wealth Management's PACB Position: Q2 2026 in Review

Kingsview Wealth Management held its Pacific Biosciences (PACB) position steady in Q2 2026 at 10,765 shares worth $18.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1414.

Kingsview Wealth Management first reported a position in PACB in Q4 2025 and has held it in 3 quarters since. The position peaked at $19.5K in Q4 2025. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Kingsview Wealth Management held 10,765 shares of Pacific Biosciences worth $18.1K as of Q2 2026.
  • Kingsview Wealth Management left its Pacific Biosciences share count unchanged in Q2 2026.
  • Pacific Biosciences made up ﹤0.01% of Kingsview Wealth Management's portfolio in Q2 2026, its #1414 holding.
  • Kingsview Wealth Management first reported a position in Pacific Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Kingsview Wealth Management's Pacific Biosciences position peaked at $19.5K in Q4 2025.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Kingsview Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.